All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Dutch Therapeutics company developing antibody-based therapy to treat cancer.
UK-based Healthtech company focused on hospital software.
UK-based digital therapy company focused on mental disorders.